Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara)
with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd)
or daratumumab SC in combination with bortezomib and dexamethasone (DVd) in Part 1 and to
evaluate the pharmacokinetics (PK), safety, and efficacy of the Tec-Dara regimen when
teclistamab is administered using a alternative dosing schedule in Part 2.
with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd)
or daratumumab SC in combination with bortezomib and dexamethasone (DVd) in Part 1 and to
evaluate the pharmacokinetics (PK), safety, and efficacy of the Tec-Dara regimen when
teclistamab is administered using a alternative dosing schedule in Part 2.
Multiple Myeloma
III
Sengsayadeth, Salyka
NCT05083169
VICCPCL2194
